Pas de connexion internet — affichage de la version enregistrée de la page.

Agios Pharm

USUSD
← Vers le screener
US:AGIOLSE:0HB0

Agios Pharm (US:AGIO) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
agios.com
Relations avec les investisseurs
investor.agios.com/
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
Cambridge, United States
PDG
Mr. Brian M. Goff M.B.A.
Employés
539
Fondée
2008
Actions en circulation
59.7 M au 2026-07-24
Flottant
50.02 M
Capitalisation boursière
2 Md USD
Initiés
1.07%
Investisseurs institutionnels
112.31%
Secteur d'activité (SIC)
Pharmaceutical Preparations
ISIN
US00847X1046
LEI
529900ONJHY8EOGYT555
Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksAGIO principaleUSD31.92 +0.41%actions ordinaires
LSE London Stock Exchange0HB0 IOBUSD33.1105 +0.00%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.10.81%6.46 M2026-06-30
Farallon Capital Managem…9.91%5.92 M2026-06-30
State Street Corporation5.92%3.53 M2026-06-30
Lynx1 Capital Management…5.71%3.41 M2026-06-30
Shaw D.E. & Co., Inc.5.2%3.11 M2026-06-30
Vanguard Portfolio Manag…4.85%2.9 M2026-06-30
Vanguard Capital Managem…4.49%2.68 M2026-06-30
Armistice Capital, LLC4.02%2.4 M2026-06-30
Erste Asset Management G…3.61%2.15 M2026-06-30
SPDR SERIES TRUST-State…3.54%2.11 M2026-08-31
Nomura Asset Management…3.54%2.11 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.16%1.89 M2026-06-30
iShares Trust-iShares Ru…2.52%1.51 M2026-07-31
VANGUARD INDEX FUNDS-Van…2.28%1.36 M2026-06-30
Delaware Group Equity Fu…1.92%1.14 M2026-05-31
VANGUARD INDEX FUNDS-Van…1.32%788 6552026-06-30
VANGUARD INDEX FUNDS-Van…1.15%683 9902026-06-30
Fidelity Salem Street Tr…1.08%646 3182026-07-31
Fidelity Rutland Square…0.88%526 1212026-07-31
iShares Trust-iShares Ru…0.86%511 9942026-07-31
FOUSE JACQUALYN A. (Dire…≈0.26%154 1562026-06-18
GHEUENS SARAH (Officer)≈0.09%54 6452026-08-04
SCADDEN DAVID T. (Direct…≈0.03%20 4192026-06-18
HO MAYKIN (Director)≈0.03%19 8482026-06-18
BALLAL RAHUL D. (Directo…≈0.03%15 2302026-06-18
SMITH CYNTHIA (Director)≈0.03%15 2302026-06-18
FOSTER-CHEEK KAYE I (Dir…≈0.02%12 4842026-06-18
ADAMS CATHERINE OWEN (Di…≈0.02%10 8652026-06-18
CAPELLO JEFFREY D (Direc…≈0.02%10 8652026-06-18
BACKSTROM JAY T (Directo…≈0%1 4472026-07-08